knowledge -WSS

knowledge

author：focus 2025-09-30 01:14:43 - browse：6233

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： What will save rural psychiatry services? Higher Medicaid payments

focus

hotspot

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

CMS got Medicare Advantage quality rating wrong, judge rules

Take antibiotics after sex, CDC recommends for certain risk groups

STAT wants to know your pick for a great summer read or listen

UnitedHealth CEO's Medicaid comments send insurer stocks diving

For pregnant people, addiction treatment shouldn't mean a call to child protective services

hotspot

knowledge

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Illumina board agrees to spin off Grail, as divestment plans proceed

What does generative AI mean for health care? We asked experts

Average age of first period drops to 11.9 years, study shows

Novavax promises a turnaround & Lilly roils the obesity market

Take antibiotics after sex, CDC recommends for certain risk groups

Sports medicine is finally prioritizing gender equality

FTC loses bid to block Novant's North Carolina hospital merger

Psychedelics group wrestles with new pharma identity

A new initiative will help leaders fight the next pandemic

hotspot

BD to buy Edwards patient monitoring unit for $4.2 billion

The most pressing bird flu mysteries scientists want answered

How CO2 helps viruses stay alive longer in the air

Do more moles mean more problems? Not so, says new study

AI used to predict Covid

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

knowledge

hotspot

focus